Non‐serious adverse events Maximum · chronic hepatitis B
It is very uncertain whether radix Sophorae flavescentis changes proportion of participants with 1 or more adverse events considered… compared with no intervention or placebo (very low certainty).
1 finding from 1 review
Proportion of participants with 1 or more serious adverse events · chronic hepatitis B
The review found no eligible studies for this question.
1 finding from 1 review
Non‐serious adverse events Maximum · chronic hepatitis B
It is very uncertain whether acupuncture changes proportion of participants with 1 or more adverse events considered… compared with no intervention (very low certainty).
1 finding from 1 review
Depressive symptoms · people with dementia
1 finding from 1 review
Neuropsychiatric symptoms · people with dementia
1 finding from 1 review
Social functioning measured using MOSES, Withdrawn Behaviour subscale (8‐ 32, higher score indicates more severe withdrawn behaviour) · people with dementia
1 finding from 1 review
Behaviour · people with dementia
1 finding from 1 review
Agitation and irritability · people with dementia
1 finding from 1 review
Number of participants with more severe DLs (severity of DLs) · Orthodontic patients of any age with fixed braces (new DLs assessed at debond)
The review found no eligible studies for this question.
1 finding from 1 review
Additional drugs required to terminate the seizure: 2 or more additional anticonvulsants required · Children with acute tonic‐clonic seizures
Summary of findings ‐ Intranasal lorazepam may leads to lower additional drugs required to terminate the seizure: 2 or more… compared with intramuscular paraldehyde (low certainty).
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · rheumatoid arthritis of the hand
2 findings from 1 review
Pain ‐ long term (12 months and beyond) Pain subscale of Michigan Hand Outcomes Questionnaire (0 to 100 points, higher score means more pain) · rheumatoid arthritis of the hand
1 finding from 1 review
Intervention not reported
Primary outcome 2: participant‐ or parent‐rated participant quality of life score at the end of active treatment Scales used: DLQI, IDQoL, Skindex‐29, CDLQI. On those scales, the higher the score, the more severely the quality of life is affected ... · male and female patients 0 to 55 years of age with physician‐diagnosed eczema
1 finding from 1 review
Intervention not reported
Primary outcome 2: participant‐ or parent‐rated family quality of life score at the end of active treatment Scale used: DFI, FDLQI. On those scales, the higher the score, the more severely the quality of life is affected Duration of · male and female patients 0 to 55 years of age with physician‐diagnosed eczema
1 finding from 1 review
Intervention not reported
Secondary outcome 4: global eczema severity score (total SCORAD) at the end of active treatment (Investigator‐rated eczema severity) Scale used: total SCORAD ranging from 0 to 103. The higher the score, the more severe the disease Duration of · male and female patients 0 to 55 years of age with physician‐diagnosed eczema
1 finding from 1 review
Activities of daily living · people with stroke
1 finding from 1 review
Adverse effects: one or more adverse events during 24 hours (only reported if occurred in ≥ 5% of people) · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether ARIPIPRAZOLE (IM) changes adverse effects: one or more adverse events during 24 hours (only… compared with OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (very low certainty).
1 finding from 1 review
Adverse effects: one or more adverse effects during 24 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether ARIPIPRAZOLE (IM) changes adverse effects: one or more adverse effects during 24 hours compared with OTHER ANTIPSYCHOTIC: b. OLANZAPINE (very low certainty).
1 finding from 1 review
Adverse effects: one or more adverse events during 24 hours (only reported if occurred in ≥ 5% of people) · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether ARIPIPRAZOLE (IM) changes adverse effects: one or more adverse events during 24 hours (only… compared with PLACEBO/NIL (very low certainty).
1 finding from 1 review
Number of participants achieving 3 or more weeks of consecutive alcohol abstinence during treatment · concurrent problem alcohol and illicit drug users
It is very uncertain whether cognitive‐behavioural coping skills training (CBCST) changes number of participants achieving 3 or more weeks of consecutive… compared with twelve‐step facilitation (TSF) programme to reduce alcohol consumption (very low certainty).
1 finding from 1 review